Relay Therapeutics Files 8-K for Material Definitive Agreement
Ticker: RLAY · Form: 8-K · Filed: Sep 11, 2024 · CIK: 1812364
| Field | Detail |
|---|---|
| Company | Relay Therapeutics, Inc. (RLAY) |
| Form Type | 8-K |
| Filed Date | Sep 11, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $7.00, $189.5 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, filing
Related Tickers: RLAY
TL;DR
RLAY signed a big deal, details TBD.
AI Summary
On September 9, 2024, Relay Therapeutics, Inc. entered into a material definitive agreement. The company, headquartered in Cambridge, MA, filed an 8-K report with the SEC detailing this event. Further specifics regarding the agreement's nature and financial implications are not detailed in the provided excerpt.
Why It Matters
This filing indicates a significant new contract or partnership for Relay Therapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which could carry significant implications, but the lack of specific details prevents a definitive risk assessment.
Key Players & Entities
- Relay Therapeutics, Inc. (company) — Registrant
- 0001193125-24-217296 (document_id) — Accession Number
- September 9, 2024 (date) — Date of earliest event reported
- 399 Binney Street, Cambridge, MA 02142 (address) — Principal Executive Offices
FAQ
What is the nature of the material definitive agreement entered into by Relay Therapeutics?
The provided excerpt does not specify the nature of the material definitive agreement.
When did Relay Therapeutics enter into this material definitive agreement?
Relay Therapeutics entered into the material definitive agreement on September 9, 2024.
What is Relay Therapeutics' principal executive office address?
Relay Therapeutics' principal executive office is located at 399 Binney Street, Cambridge, Massachusetts 02142.
What is the SEC file number for Relay Therapeutics?
The SEC file number for Relay Therapeutics is 001-39385.
What is the SIC code for Relay Therapeutics?
The Standard Industrial Classification (SIC) code for Relay Therapeutics is 2836, for Biological Products (No Diagnostic Substances).
Filing Stats: 1,158 words · 5 min read · ~4 pages · Grade level 12.6 · Accepted 2024-09-11 16:49:02
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share RLAY Nasdaq Global Market
- $7.00 — on Stock"), at a price to the public of $7.00 per share. The Company granted the Unde
- $189.5 m — e by the Company, will be approximately $189.5 million, excluding any exercise of the Un
Filing Documents
- d892276d8k.htm (8-K) — 32KB
- d892276dex11.htm (EX-1.1) — 190KB
- d892276dex51.htm (EX-5.1) — 6KB
- d892276dex991.htm (EX-99.1) — 9KB
- d892276dex992.htm (EX-99.2) — 9KB
- g892276dsp50.jpg (GRAPHIC) — 6KB
- 0001193125-24-217296.txt ( ) — 437KB
- rlay-20240909.xsd (EX-101.SCH) — 3KB
- rlay-20240909_lab.xml (EX-101.LAB) — 17KB
- rlay-20240909_pre.xml (EX-101.PRE) — 11KB
- d892276d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 1.1 Underwriting Agreement, dated as of September 10, 2024, by and among the Company, Goldman Sachs & Co. LLC and TD Securities (USA) LLC, as representatives of the several Underwriters listed on Schedule 1 thereto. 5.1 Opinion of Goodwin Procter LLP regarding the issue of Common Stock being registered. 23.1 Consent of Goodwin Procter LLP (included in Exhibit 5.1). 99.1 Press release for the launch of the Offering issued by the Company on September 9, 2024. 99.2 Press release for the pricing of the Offering issued by the Company on September 10, 2024. 104 Cover Page Interactive Data File (embedded within Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RELAY THERAPEUTICS, INC. Date: September 11, 2024 By: /s/ Brian Adams Brian Adams Chief Legal Officer